Bibliografía

1. Helmick CG, Felson DT, Lawrence RC. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008; 58:15-25.
2. Lawrence RC, Felson DT, Helmick CG. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008; 58:26-35.
3. Weaver AL. Epidemiology of gout. Cleve Clin J Med. 2008; 75(suppl 5):S9-S12.
4. Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout. Bull NYU Hosp Jt Dis. 2007; 65:215-21.
5. Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006; 8(suppl 1):S1.
6. Dore RK. Gout: what primary care physicians want to know. J Clin Rheumatol. 2008; 14(suppl 5):S47-S54.
7. Weaver AL, Cheh MA, Kennison RH. How PCP education can impact gout management: the gout essentials. J Clin Rheumatol. 2008; 14(suppl):S42-S46.
8. Mandel DA, Simkin PA. Gout: update on pathogenesis, diagnosis, and treatment. New Develop Rheum Dis. 2007; 4(3) 20-5.
9. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005; 143:499-516.
10. Wyngaarden JB. The role of the kidney in pathogenesis and treatment of gout. Arthritis Rheum. 1958; 1:191-203.
11. Choi HK, Atkinson K, Karlson EW. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow up study. Arch Intern Med. 2005; 165:742-8.
12. Choi HK, Atkinson K, Karlson EWl. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004; 363:1277-81.
13. Choi HK, Atkinson K, Karlson EW. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004; 350:1093-8.
14. Pillinger MH, Keenan RT. Update on the management of hyperuricemia and gout. Bull NYU Hosp Jt Dis. 2008; 66:231-9.
15. Emmerson BT. Effect of oral fructose on urate production. Ann Rheum Dis. 1974; 33:276-80.
16. Choi JW, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008; 59:109-16.
17. Schlesinger N, Schumacher HR. Update on gout. Arthritis Rheum. 2002; 47:563-5.
18. Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am. 1990; 16:539-50.
19. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004; 31:1582-87.
20. Hawkins DW, Rahn DW. Gout and hyperuricemia. En: DiPiro JT, Talbert RL, Yee GC, Ed. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. New York, NY: Editorial McGraw-Hill; 2002.p.1659-64.
21. Becker MA, Jolly M. Clinical gout and the pathogenesis of hyperuricemia. In: Koopman WJ, Moreland LW, eds. Arthritis and Allied Conditions. 15th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:2303-39.
22. Worthmann PL, Kelly WN. Gout and hyperuricemia. In: Harris ED Jr, Budd RC, Genovese MC, et al, eds. Kelly;s Textbook of Rheumatology. 7th ed. Philadelphia, PA: WB Saunders Company; 2005:1402-29.
23. Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008; 75(suppl 5):S5-S8.
24. Dalbeth N, McQueen FM. Use of imaging to evaluate gout and other crystal deposition disorders. Curr Opin Rheumatol. 2009; 21:124-31.
25. Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol. 2008; 20:167-72.
26. Zhang W, Doherty M, Bardin T. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65:1312-24.
27. Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol. 2007; 19:122-27.
28. Li-Yu J, Clayburne G, Sieck M. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001; 28:577-80.
29. Van Heyningen C, Watson ID. Troponin for prediction of cardiovascular collapse in acute colchicine overdose. Emerg Med J. 2005; 22:599-600.
30. Schumacher HR Jr, Chen LX. The practical management of gout. Cleve Clin J Med. 2008; 75(suppl 5):S22-S25.
31. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs. 2004; 64:2399-2416.
32. Eggebeen AT. Gout: an update. Am Fam Physician. 2007; 76:801-808.
33. Becker MA, Schumacher HR, Wortmann RL. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353:2450-2461.
34. Deerfield, IL. Uloric (febuxostat) package insert: Takeda Pharmaceuticals North America; February 2009. Disponible en: www.uloric.com. A ultimo acceso Abril 2010.
35. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant. 2005; 20:431-33.
36. Biggers K, Scheinfeld N. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. Curr Opin Investig Drugs. 2008; 9:422-42.
37. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; 8(suppl 1):S4.
38. Martinon F, Petrilli V, Mayor Al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440:237-41.